FDA Approves CRYSVITA — Kyowa Kirin, Inc.

# FDA Approves Kyowa Kirin's CRYSVITA for X-Linked Hypophosphatemia Treatment Kyowa Kirin, Inc. received FDA approval for CRYSVITA (burosumab), a first-in-class subcutaneous therapy that addresses a significant unmet need in rare bone disease treatment and positions the company to capture a specialized market segment with limited competition. The approval of this novel mechanism of action represents a potentially lucrative opportunity in the rare disease space, where patient populations, though small, typically command premium pricing and lower competitive pressures.